Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.

Chronic Chagas cardiomyopathy (CCC) is one of the leading causes of morbidity and mortality due to cardiovascular disorders in endemic areas of Chagas disease (CD), a neglected tropical illness caused by the protozoan parasite Trypanosoma cruzi. CCC is characterized by parasite persistence and infla...

Full description

Bibliographic Details
Published in:	PLoS Neglected Tropical Diseases
Main Authors:	Priscila Silva Grijó Farani, Beatriz Iandra da Silva Ferreira, Khodeza Begum, Glaucia Vilar-Pereira, Isabela Resende Pereira, Edith A Fernández-Figueroa, Roberto Alejandro Cardenas-Ovando, Igor C Almeida, Sourav Roy, Joseli Lannes-Vieira, Otacilio Cruz Moreira
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2023-03-01
Online Access:	https://doi.org/10.1371/journal.pntd.0011223

Similar Items

Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease
by: Isabela Resende Pereira, et al.
Published: (2014-06-01)

Tumor Necrosis Factor Is a Therapeutic Target for Immunological Unbalance and Cardiac Abnormalities in Chronic Experimental Chagas’ Heart Disease
by: Isabela Resende Pereira, et al.
Published: (2014-01-01)

Behavioural alterations are independent of sickness behaviour in chronic experimental Chagas disease
by: Glaucia Vilar-Pereira, et al.
Published: (2015-12-01)

Treatments and the Perspectives of Developing a Vaccine for Chagas Disease
by: Priscila Silva Grijó Farani, et al.
Published: (2024-08-01)

Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole
by: Bianca Sabaini Pavan Tycha, et al.
Published: (2023-01-01)

Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease
by: Lucas Resende Dutra Sousa, et al.
Published: (2024-06-01)

The beneficial effect of fluoxetine on behavioral and cognitive changes in chronic experimental Chagas disease unveils the role of serotonin fueling astrocyte infection by Trypanosoma cruzi.
by: Glaucia Vilar-Pereira, et al.
Published: (2024-05-01)

Access to benznidazole for Chagas disease in the United States-Cautious optimism?
by: Jonathan D Alpern, et al.
Published: (2017-09-01)

Long term evaluation of etiological treatment of Chagas disease with benznidazole
by: J. Romeu CANÇADO
Published: (2002-02-01)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022-08-01)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
by: Cristina Vázquez, et al.
Published: (2023-01-01)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease.
by: Abilio Augusto Fragata-Filho, et al.
Published: (2016-03-01)

Parasitemia and antibody response to benznidazole treatment in a cohort of patients with chronic Chagas disease
by: Carlos Henrique Valente Moreira, et al.
Published: (2023-09-01)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
by: Ana Lia Mazzeti, et al.
Published: (2023-04-01)

Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
by: Margoth Moreno, et al.
Published: (2010-11-01)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
by: Elena Aguilera, et al.

Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease.
by: Ana Yecê das Neves Pinto, et al.
Published: (2013-01-01)

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.
by: Mario J Olivera, et al.
Published: (2017-01-01)

Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.
by: Glaucia Diniz Alessio, et al.
Published: (2024-09-01)

Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA).
by: Frauke Assmus, et al.
Published: (2025-09-01)

Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease.
by: Frauke Assmus, et al.
Published: (2025-05-01)

Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil
by: Joao Manoel Rossi Neto, et al.
Published: (2020-08-01)

Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease
by: Ágata C. Cevey, et al.
Published: (2017-12-01)

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
by: Agustín Ciapponi, et al.
Published: (2020-08-01)

A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention
by: Girley Francisco Machado-de-Assis, et al.
Published: (2013-11-01)

Enfermedad de Chagas aguda, en un adulto tratado con benznidazol (Rochagan®) en Costa Rica
by: Víctor M. Montenegro, et al.
Published: (2004-06-01)

Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole
by: Melisa D. Castro Eiro, et al.
Published: (2022-08-01)

Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?
by: Maria Jose Morilla, et al.
Published: (2005-04-01)

Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease
by: Jaquelline Carla Valamiel de Oliveira-Silva, et al.
Published: (2015-02-01)

Resveratrol Reverses Functional Chagas Heart Disease in Mice.
by: Glaucia Vilar-Pereira, et al.
Published: (2016-10-01)

Caracterização físico-química do fármaco antichagásico benznidazol Physicochemical characterization of antichagasic benznidazole
by: Flávia Pires Maximiano, et al.
Published: (2010-01-01)

Redução dos Níveis de Insulina em Pacientes com Doença de Chagas Aguda na Amazônia Brasileira Tratados com Benznidazol
by: João Marcos Barbosa-Ferreira, et al.
Published: (2025-05-01)

Effects of pentoxifylline in patients with chronic Chagas cardiomyopathy: A randomized, double-blind, controlled pilot trial.
by: Káryta Suely Macêdo Martins, et al.
Published: (2025-10-01)

Causalidade e Gravidade das Reações Adversas e Alterações Laboratoriais ao Tratamento com Benznidazol em Pacientes com Doença de Chagas Crônica
by: Alanna Carla da Costa Belmino, et al.
Published: (2024-09-01)

Diseño y preparación de formas farmacéuticas sólidas de benznidazol para el tratamiento de la enfermedad de Chagas
by: Sonia, Tarragona, et al.
Published: (2013-05-01)

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
by: Leticia L Niborski, et al.
Published: (2016-06-01)

The centennial of the discovery of Chagas disease: facing the current challenges.
by: Joseli Lannes-Vieira, et al.
Published: (2010-01-01)

Investigation of the effects of benznidazole on the salivary glands: A biochemical, morphological, and functional approach
by: Emanuelly Camilly Soares de Lima-da-Silva, et al.
Published: (2025-01-01)

The expression of immune response genes in patients with chronic Chagas disease is shifted toward the levels observed in healthy subjects as a result of treatment with Benznidazole
by: Inmaculada Gómez, et al.
Published: (2024-07-01)

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial
by: Anis Rassi Jr, et al.